Implementation of the NICE guidelines for venous thromboprophylaxis; A national survey of hip surgeons

HIP International

Volumn 19, Issue 1, 2009, Pages 58-63

  Sharif, Khalid M ^a,b   Rehman, Sheikh Fazal ^a   Nunn, Timothy ^a   Bagga, Tajesh K ^a  

^a DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Fracture; Hip; Prophylaxis; Replacement; Thrombosis; Venous

Indexed keywords

ACETYLSALICYLIC ACID; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTICLE; CLINICAL PROTOCOL; COMPRESSION THERAPY; HEALTH SURVEY; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; PRACTICE GUIDELINE; QUESTIONNAIRE; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TREATMENT DURATION; VEIN THROMBOSIS;

EID: 66649112509     PISSN: 11207000     EISSN: None     Source Type: Journal    
DOI: 10.1177/112070000901900111     Document Type: Article

References (33)

1. Turpie AG, Levine M, Hirsh Jack, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomised Controlled Trial of a low Molecular-Weight Heparin (Enoxaparin) to prevent Deep-Vein Thrombosis in patients undergoing elective Hip Surgery. New England J Med 1986; 315: 925-9.
2. Howie C, Hughes H, Watts AC. Venous thrombosis prophylaxis associated with hip and knee replacement over a ten year period a population based study. J Bone Joint Surg Br 2005; 87-B: 1675-80.
3. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006; 98-B: 386-91.
4. Murray DW, Britton AR, Bulstrode CJK. Thromboprophylaxis and death after total Hip Replacement. J Bone Joint Surg Br 1996; 78-B: 863-70.
5. Fender D, Harper WM, Thompson Jr, Gregg PJ. Mortality and fatal pulmonary embolism post primary total hip replacement: Results from a region hip register. J Bone Joint Surg Br 1997; 79-B: 896-9.
6. Warick D, Dahl OE, Fisher WD. orthopaedic thromboprophylaxis limitations of current guidelines. J Bone Joint Surg Br 2008; 90-B: 127-32.
7. No authors listed. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in in-patients undergoing surgery. Quick reference guide. Issued by the National Institute of Health and Clinical Excellence, UK, April 2007. http://www.nice.org.uk/nicemedia/pdf/CG046quickrefguide.pdf
8. No author listed House of Commons health committee. The prevention of venous thromboembolism in hospitalised patients, second report of session 2004-05. March 2005. Http://www.dh.gov.ukvte
9. Abraham A, Hajipoor L, Innes AR, Phillips H, Mc Caskie AW. Are national guidelines for total hip replacement in UK reflected in practice? Ann R Coll Surg Eng 2006: 88: 108-15.
10. Brenkelij, Clancy MJ. Total hip replacement and anti thrombotic prophylaxis. Br J Hosp Med 1989; 42: 282-4.
11. Laverick MD, Croal SA, Mollan RAB. orthopaedic Surgeons and thromboprophylaxis Br Med J 1991; 303: 549-50.
12. Campling EA, Devlin HB, Hoile RW, Lunn JN. The report of the National Confidential enquiry in to perioperative deaths 1991-1992. NCEPOD, London.
13. Unwin AJ, Jones Jr, Harris WJ. Current UK opinion on thromboprophylaxis in Orthopaedic surgery: Its use in routine total hip and knee arthroplasty. Ann R Coll Surg Engl 1995; 77: 351-4.
14. Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H, et al. Optimal Low molecular weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost 2003, 90: 654-61.
15. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
16. Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty a meta-analysis. Thromb Haemost 2001; 85: 940-1.
17. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.
18. Innohep (tinzaparin sodium injection) package insert. Wilmington, DE: Dupont Pharma; 2000 Jul.
19. Fegan CD. Tinzaparin as an antithrombotic: An overview. Hosp Med 1998; 59: 145-8.
20. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
21. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
22. Hull RD, Raskob GE, Brant RF, et al. Low molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000; 160: 229-36.
23. Abramowicz M, ed. Tinzaparin: A low molecular weight heparin for treatment of deep vein thrombosis. Med Lett Drugs Ther 2001; 43: 14-5.
24. Friedel H, Balfour JA. Tinzaparin: A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 1994; 48: 638-60.
25. Parry M, Wylde V, Blom AW. Ninety-day mortality after elective total hip replacement 1549 patients using Aspirin as a thromboprophylactic agent. J Bone Joint Surg Br 2008; 90-B: 306-7.
26. Nicolaides AN, Fareed J, Kakkar AK, Breddin HK, Goldhaber SZ, Hull R, Kakkar VV, Michels JJ, Myers K, Samama M, Sasahara A. Prevention and treatment of venous thromboembolism International Consensus Statement (Guidelines according to scientific evidence). Int Angiol 2006; 25: 101-61.
27. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous Thromboembolism American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 2008; 133: 381S-453S.
28. Watts AC, Howie CR, Simpson AHRW. Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Br 2006; 88-B: 107-10.
29. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial Lancet 2000; 355: 1295-302.
30. Eriksson BI, Lassen MR for the PEN. Tasaccharide in Hip-FRActure Surgery Plus (PENTHRIFRA PLUS) investigators. Duration of prophylaxis against Venous Thromboembolism with Fondaparinux after Hip Fracture Surgery. Arch Intern Med 2003; 163: 1337-42.
31. Lassen MR Bauer KA Eriksson BI Turpie AGG. Posoperative fondararinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: A randomized double blind comparison. Lancet 2002; 359: 1715-20.
32. Watts AC, Brenkel IJ. Postal Survey of current Thromboprophylactic practice of consultant orthopaedic surgeons in the treatment of fracture of the hip. J Bone Joint Surg Br 2005; 87-B: 296-300.
33. Singelyn FJ, Verheyen CC, Piovella F, Van Aken HK, Rosencher N. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter. Anesth Analg 2007; 105: 1540-7.